Therapeutic impact of determination of RAS mutations in the plasma of patients with colorectal cancer Impact of RAS mutations in colorectal cancer
Gastroenterology and Hepatology from Bed to Bench,
Introduction: Stage IV colorectal cancer treatment include targeted therapy depending on RAS status. During disease progression, loss or gain of RAS mutations could happen, supporting the hypothesis of evolutionary pressure of therapy. Circulating tumor DNA (ctDNA) are nucleic acids released to the bloodstream by the tumor during its development and could be detected by liquid biopsy.
Methods: The Idylla© Biocartis, a fully automated real-time-PCR based molecular diagnostic system, was used in a patient with metastatic colorectal cancer with a NRAS mutation in progression after several therapeutic lines.
Results: The ctDNA mutational analysis was performed and revealed the absence of mutations in KRAS, NRAS, and BRAF genes. The patient started the third line of palliative chemotherapy with irinotecan + cetuximab and achieved for the first-time partial response.
Conclusion: The authors describe a case were liquid biopsy determined the higher progression free survival achieved.
- Colorectal Cancer; Ras Gene; real time PCR; circulating tumor cell; Molecular targeted therapies.
How to Cite
2 - Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12(1):38–50.
3 - T. Yoshino, D. Arnold, H. Taniguchi, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Annals of Oncology. 2018; 29: 44–70.
4 - Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–1417.
5 - De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762.
6 - Diaz LA, Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–540.
7 - Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 2005;102(45):16368–16373
8 - Kriegsmann M, Arens N, Endris V, Weichert W, Kriegsmann J. Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique. Diagn Pathol. 2015;10:132.
9 - Holdhoff M, Schmidt K, Donehower R, Diaz LA., Jr Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst. 2009;101(18):1284–1285.
10 - Siravegna G., Marsoni S., Siena S., Bardelli A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 2017;14:531–548.
11 - Oshima K., Khiabanian H., da Silva-Almeida A.C., et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA. 2016;113:11306–11311.
12 – Raimondi C, Nicolazzo C, Belardinilli F, et al. Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer. Cancers. 2019 Jan; 11(1): 42.
- Abstract Viewed: 0 times
- pdf Downloaded: 0 times